nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—ovarian cancer	0.47	1	CbGaD
Dihydroergotamine—ABCB1—Topotecan—ovarian cancer	0.066	0.221	CbGbCtD
Dihydroergotamine—ABCB1—Vinorelbine—ovarian cancer	0.0465	0.156	CbGbCtD
Dihydroergotamine—CYP3A4—Topotecan—ovarian cancer	0.0395	0.133	CbGbCtD
Dihydroergotamine—ABCB1—Paclitaxel—ovarian cancer	0.0326	0.11	CbGbCtD
Dihydroergotamine—CYP3A4—Vinorelbine—ovarian cancer	0.0278	0.0935	CbGbCtD
Dihydroergotamine—ABCB1—Docetaxel—ovarian cancer	0.0236	0.0792	CbGbCtD
Dihydroergotamine—CYP3A4—Paclitaxel—ovarian cancer	0.0196	0.0657	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—ovarian cancer	0.0176	0.0591	CbGbCtD
Dihydroergotamine—CYP3A4—Docetaxel—ovarian cancer	0.0141	0.0475	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—ovarian cancer	0.0105	0.0354	CbGbCtD
Dihydroergotamine—HTR2B—myometrium—ovarian cancer	0.000493	0.0689	CbGeAlD
Dihydroergotamine—Menopausal symptoms—Epirubicin—ovarian cancer	0.000428	0.00191	CcSEcCtD
Dihydroergotamine—Pruritus—Topotecan—ovarian cancer	0.000427	0.00191	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000426	0.0019	CcSEcCtD
Dihydroergotamine—Asthenia—Melphalan—ovarian cancer	0.000424	0.00189	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000423	0.00188	CcSEcCtD
Dihydroergotamine—Pruritus—Melphalan—ovarian cancer	0.000418	0.00187	CcSEcCtD
Dihydroergotamine—Tension—Paclitaxel—ovarian cancer	0.000418	0.00186	CcSEcCtD
Dihydroergotamine—Rhinitis—Docetaxel—ovarian cancer	0.000416	0.00185	CcSEcCtD
Dihydroergotamine—Eye pain—Doxorubicin—ovarian cancer	0.000414	0.00185	CcSEcCtD
Dihydroergotamine—Nervousness—Paclitaxel—ovarian cancer	0.000414	0.00184	CcSEcCtD
Dihydroergotamine—Diarrhoea—Topotecan—ovarian cancer	0.000413	0.00184	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000413	0.00184	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000413	0.00184	CcSEcCtD
Dihydroergotamine—Pharyngitis—Docetaxel—ovarian cancer	0.000412	0.00184	CcSEcCtD
Dihydroergotamine—Urticaria—Vinorelbine—ovarian cancer	0.000411	0.00183	CcSEcCtD
Dihydroergotamine—Muscle spasms—Paclitaxel—ovarian cancer	0.000409	0.00183	CcSEcCtD
Dihydroergotamine—Abdominal pain—Vinorelbine—ovarian cancer	0.000409	0.00182	CcSEcCtD
Dihydroergotamine—Body temperature increased—Vinorelbine—ovarian cancer	0.000409	0.00182	CcSEcCtD
Dihydroergotamine—Diarrhoea—Melphalan—ovarian cancer	0.000405	0.0018	CcSEcCtD
Dihydroergotamine—Nausea—Chlorambucil—ovarian cancer	0.000403	0.0018	CcSEcCtD
Dihydroergotamine—Hot flush—Doxorubicin—ovarian cancer	0.0004	0.00178	CcSEcCtD
Dihydroergotamine—Visual impairment—Docetaxel—ovarian cancer	0.0004	0.00178	CcSEcCtD
Dihydroergotamine—Dizziness—Topotecan—ovarian cancer	0.000399	0.00178	CcSEcCtD
Dihydroergotamine—Tremor—Paclitaxel—ovarian cancer	0.000399	0.00178	CcSEcCtD
Dihydroergotamine—Migraine—Epirubicin—ovarian cancer	0.000398	0.00177	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000396	0.00177	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000395	0.00176	CcSEcCtD
Dihydroergotamine—Agitation—Paclitaxel—ovarian cancer	0.000391	0.00175	CcSEcCtD
Dihydroergotamine—Face oedema—Epirubicin—ovarian cancer	0.00039	0.00174	CcSEcCtD
Dihydroergotamine—Flushing—Docetaxel—ovarian cancer	0.000385	0.00172	CcSEcCtD
Dihydroergotamine—Vomiting—Topotecan—ovarian cancer	0.000384	0.00171	CcSEcCtD
Dihydroergotamine—Malaise—Paclitaxel—ovarian cancer	0.000384	0.00171	CcSEcCtD
Dihydroergotamine—HTR2B—uterine cervix—ovarian cancer	0.000384	0.0536	CbGeAlD
Dihydroergotamine—Vertigo—Paclitaxel—ovarian cancer	0.000383	0.00171	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000382	0.0017	CcSEcCtD
Dihydroergotamine—Rash—Topotecan—ovarian cancer	0.000381	0.0017	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000381	0.0017	CcSEcCtD
Dihydroergotamine—Dermatitis—Topotecan—ovarian cancer	0.000381	0.0017	CcSEcCtD
Dihydroergotamine—Headache—Topotecan—ovarian cancer	0.000378	0.00169	CcSEcCtD
Dihydroergotamine—Palpitations—Paclitaxel—ovarian cancer	0.000376	0.00168	CcSEcCtD
Dihydroergotamine—Vomiting—Melphalan—ovarian cancer	0.000376	0.00168	CcSEcCtD
Dihydroergotamine—Rash—Melphalan—ovarian cancer	0.000373	0.00166	CcSEcCtD
Dihydroergotamine—Dermatitis—Melphalan—ovarian cancer	0.000373	0.00166	CcSEcCtD
Dihydroergotamine—Chills—Docetaxel—ovarian cancer	0.000372	0.00166	CcSEcCtD
Dihydroergotamine—Asthenia—Vinorelbine—ovarian cancer	0.000371	0.00165	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—ovarian cancer	0.000368	0.00164	CcSEcCtD
Dihydroergotamine—Hypertension—Paclitaxel—ovarian cancer	0.000368	0.00164	CcSEcCtD
Dihydroergotamine—HTR2B—decidua—ovarian cancer	0.000366	0.0511	CbGeAlD
Dihydroergotamine—Pruritus—Vinorelbine—ovarian cancer	0.000366	0.00163	CcSEcCtD
Dihydroergotamine—Myalgia—Paclitaxel—ovarian cancer	0.000363	0.00162	CcSEcCtD
Dihydroergotamine—Arthralgia—Paclitaxel—ovarian cancer	0.000363	0.00162	CcSEcCtD
Dihydroergotamine—Anxiety—Paclitaxel—ovarian cancer	0.000361	0.00161	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—ovarian cancer	0.000361	0.00161	CcSEcCtD
Dihydroergotamine—Nausea—Topotecan—ovarian cancer	0.000359	0.0016	CcSEcCtD
Dihydroergotamine—Discomfort—Paclitaxel—ovarian cancer	0.000358	0.0016	CcSEcCtD
Dihydroergotamine—Muscular weakness—Epirubicin—ovarian cancer	0.000357	0.00159	CcSEcCtD
Dihydroergotamine—Dry mouth—Paclitaxel—ovarian cancer	0.000355	0.00158	CcSEcCtD
Dihydroergotamine—Diarrhoea—Vinorelbine—ovarian cancer	0.000354	0.00158	CcSEcCtD
Dihydroergotamine—Nausea—Melphalan—ovarian cancer	0.000351	0.00157	CcSEcCtD
Dihydroergotamine—Confusional state—Paclitaxel—ovarian cancer	0.00035	0.00156	CcSEcCtD
Dihydroergotamine—Dysphagia—Epirubicin—ovarian cancer	0.000349	0.00156	CcSEcCtD
Dihydroergotamine—Oedema—Paclitaxel—ovarian cancer	0.000348	0.00155	CcSEcCtD
Dihydroergotamine—HTR2B—endometrium—ovarian cancer	0.000347	0.0485	CbGeAlD
Dihydroergotamine—Muscle spasms—Docetaxel—ovarian cancer	0.000347	0.00155	CcSEcCtD
Dihydroergotamine—Shock—Paclitaxel—ovarian cancer	0.000342	0.00152	CcSEcCtD
Dihydroergotamine—Dizziness—Vinorelbine—ovarian cancer	0.000342	0.00152	CcSEcCtD
Dihydroergotamine—Angina pectoris—Epirubicin—ovarian cancer	0.00034	0.00152	CcSEcCtD
Dihydroergotamine—Tachycardia—Paclitaxel—ovarian cancer	0.000339	0.00151	CcSEcCtD
Dihydroergotamine—Bronchitis—Epirubicin—ovarian cancer	0.000336	0.0015	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000336	0.0015	CcSEcCtD
Dihydroergotamine—Anorexia—Paclitaxel—ovarian cancer	0.000331	0.00148	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—ovarian cancer	0.00033	0.00147	CcSEcCtD
Dihydroergotamine—Vomiting—Vinorelbine—ovarian cancer	0.000329	0.00147	CcSEcCtD
Dihydroergotamine—Rash—Vinorelbine—ovarian cancer	0.000326	0.00145	CcSEcCtD
Dihydroergotamine—Dermatitis—Vinorelbine—ovarian cancer	0.000326	0.00145	CcSEcCtD
Dihydroergotamine—Hypotension—Paclitaxel—ovarian cancer	0.000325	0.00145	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000325	0.00145	CcSEcCtD
Dihydroergotamine—Headache—Vinorelbine—ovarian cancer	0.000324	0.00144	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—ovarian cancer	0.000323	0.00144	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—ovarian cancer	0.000323	0.00144	CcSEcCtD
Dihydroergotamine—HTR2B—uterus—ovarian cancer	0.00032	0.0447	CbGeAlD
Dihydroergotamine—HTR1B—female reproductive system—ovarian cancer	0.000319	0.0446	CbGeAlD
Dihydroergotamine—Palpitations—Docetaxel—ovarian cancer	0.000319	0.00142	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000317	0.00141	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—ovarian cancer	0.000315	0.0014	CcSEcCtD
Dihydroergotamine—Insomnia—Paclitaxel—ovarian cancer	0.000314	0.0014	CcSEcCtD
Dihydroergotamine—Paraesthesia—Paclitaxel—ovarian cancer	0.000312	0.00139	CcSEcCtD
Dihydroergotamine—Hypertension—Docetaxel—ovarian cancer	0.000312	0.00139	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—ovarian cancer	0.000311	0.00139	CcSEcCtD
Dihydroergotamine—Dyspnoea—Paclitaxel—ovarian cancer	0.00031	0.00138	CcSEcCtD
Dihydroergotamine—ADRA2A—myometrium—ovarian cancer	0.00031	0.0433	CbGeAlD
Dihydroergotamine—HTR1D—female reproductive system—ovarian cancer	0.000309	0.0432	CbGeAlD
Dihydroergotamine—Somnolence—Paclitaxel—ovarian cancer	0.000309	0.00138	CcSEcCtD
Dihydroergotamine—Arthralgia—Docetaxel—ovarian cancer	0.000307	0.00137	CcSEcCtD
Dihydroergotamine—Myalgia—Docetaxel—ovarian cancer	0.000307	0.00137	CcSEcCtD
Dihydroergotamine—Nausea—Vinorelbine—ovarian cancer	0.000307	0.00137	CcSEcCtD
Dihydroergotamine—Dyspepsia—Paclitaxel—ovarian cancer	0.000306	0.00136	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—ovarian cancer	0.000303	0.00135	CcSEcCtD
Dihydroergotamine—Decreased appetite—Paclitaxel—ovarian cancer	0.000302	0.00135	CcSEcCtD
Dihydroergotamine—Dry mouth—Docetaxel—ovarian cancer	0.000301	0.00134	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000301	0.00134	CcSEcCtD
Dihydroergotamine—Fatigue—Paclitaxel—ovarian cancer	0.0003	0.00134	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—ovarian cancer	0.000299	0.00133	CcSEcCtD
Dihydroergotamine—Pain—Paclitaxel—ovarian cancer	0.000297	0.00133	CcSEcCtD
Dihydroergotamine—Confusional state—Docetaxel—ovarian cancer	0.000297	0.00132	CcSEcCtD
Dihydroergotamine—Oedema—Docetaxel—ovarian cancer	0.000295	0.00131	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—ovarian cancer	0.000294	0.00131	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—ovarian cancer	0.000292	0.0013	CcSEcCtD
Dihydroergotamine—Shock—Docetaxel—ovarian cancer	0.00029	0.00129	CcSEcCtD
Dihydroergotamine—HTR2B—female reproductive system—ovarian cancer	0.000288	0.0402	CbGeAlD
Dihydroergotamine—Tachycardia—Docetaxel—ovarian cancer	0.000288	0.00128	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000286	0.00128	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000284	0.00127	CcSEcCtD
Dihydroergotamine—Anorexia—Docetaxel—ovarian cancer	0.000281	0.00125	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—ovarian cancer	0.00028	0.00125	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—ovarian cancer	0.00028	0.00125	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000278	0.00124	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—ovarian cancer	0.000278	0.00124	CcSEcCtD
Dihydroergotamine—Urticaria—Paclitaxel—ovarian cancer	0.000276	0.00123	CcSEcCtD
Dihydroergotamine—Hypotension—Docetaxel—ovarian cancer	0.000275	0.00123	CcSEcCtD
Dihydroergotamine—Body temperature increased—Paclitaxel—ovarian cancer	0.000275	0.00123	CcSEcCtD
Dihydroergotamine—Abdominal pain—Paclitaxel—ovarian cancer	0.000275	0.00123	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—ovarian cancer	0.000272	0.00121	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—ovarian cancer	0.00027	0.00121	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—ovarian cancer	0.00027	0.0012	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000268	0.0012	CcSEcCtD
Dihydroergotamine—Insomnia—Docetaxel—ovarian cancer	0.000266	0.00119	CcSEcCtD
Dihydroergotamine—Paraesthesia—Docetaxel—ovarian cancer	0.000265	0.00118	CcSEcCtD
Dihydroergotamine—Dyspnoea—Docetaxel—ovarian cancer	0.000263	0.00117	CcSEcCtD
Dihydroergotamine—Somnolence—Docetaxel—ovarian cancer	0.000262	0.00117	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—ovarian cancer	0.000261	0.00116	CcSEcCtD
Dihydroergotamine—HTR2B—vagina—ovarian cancer	0.00026	0.0363	CbGeAlD
Dihydroergotamine—Flushing—Epirubicin—ovarian cancer	0.00026	0.00116	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—ovarian cancer	0.000259	0.00116	CcSEcCtD
Dihydroergotamine—Dyspepsia—Docetaxel—ovarian cancer	0.000259	0.00116	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000258	0.00115	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—ovarian cancer	0.000257	0.00115	CcSEcCtD
Dihydroergotamine—Decreased appetite—Docetaxel—ovarian cancer	0.000256	0.00114	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000256	0.00114	CcSEcCtD
Dihydroergotamine—Fatigue—Docetaxel—ovarian cancer	0.000254	0.00113	CcSEcCtD
Dihydroergotamine—Pain—Docetaxel—ovarian cancer	0.000252	0.00112	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—ovarian cancer	0.000251	0.00112	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—ovarian cancer	0.000249	0.00111	CcSEcCtD
Dihydroergotamine—Asthenia—Paclitaxel—ovarian cancer	0.000249	0.00111	CcSEcCtD
Dihydroergotamine—Pruritus—Paclitaxel—ovarian cancer	0.000246	0.0011	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Docetaxel—ovarian cancer	0.000243	0.00108	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—ovarian cancer	0.000241	0.00108	CcSEcCtD
Dihydroergotamine—ADRA2A—uterine cervix—ovarian cancer	0.000241	0.0337	CbGeAlD
Dihydroergotamine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000241	0.00107	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—ovarian cancer	0.00024	0.00107	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—ovarian cancer	0.000239	0.00107	CcSEcCtD
Dihydroergotamine—Diarrhoea—Paclitaxel—ovarian cancer	0.000238	0.00106	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—ovarian cancer	0.000236	0.00105	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—ovarian cancer	0.000234	0.00104	CcSEcCtD
Dihydroergotamine—Abdominal pain—Docetaxel—ovarian cancer	0.000233	0.00104	CcSEcCtD
Dihydroergotamine—Body temperature increased—Docetaxel—ovarian cancer	0.000233	0.00104	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—ovarian cancer	0.000232	0.00104	CcSEcCtD
Dihydroergotamine—Dizziness—Paclitaxel—ovarian cancer	0.00023	0.00102	CcSEcCtD
Dihydroergotamine—ADRA2A—decidua—ovarian cancer	0.00023	0.0321	CbGeAlD
Dihydroergotamine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000226	0.00101	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—ovarian cancer	0.000224	0.000998	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—ovarian cancer	0.000221	0.000986	CcSEcCtD
Dihydroergotamine—Vomiting—Paclitaxel—ovarian cancer	0.000221	0.000985	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—ovarian cancer	0.00022	0.000979	CcSEcCtD
Dihydroergotamine—Rash—Paclitaxel—ovarian cancer	0.000219	0.000977	CcSEcCtD
Dihydroergotamine—Dermatitis—Paclitaxel—ovarian cancer	0.000219	0.000976	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—ovarian cancer	0.000219	0.000976	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—ovarian cancer	0.000219	0.000975	CcSEcCtD
Dihydroergotamine—ADRA2A—endometrium—ovarian cancer	0.000218	0.0305	CbGeAlD
Dihydroergotamine—Headache—Paclitaxel—ovarian cancer	0.000218	0.000971	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Docetaxel—ovarian cancer	0.000217	0.000968	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—ovarian cancer	0.000217	0.000966	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—ovarian cancer	0.000215	0.000959	CcSEcCtD
Dihydroergotamine—Asthenia—Docetaxel—ovarian cancer	0.000211	0.000943	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—ovarian cancer	0.00021	0.000937	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000209	0.000932	CcSEcCtD
Dihydroergotamine—Pruritus—Docetaxel—ovarian cancer	0.000208	0.000929	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—ovarian cancer	0.000207	0.000924	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—ovarian cancer	0.000207	0.000924	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—ovarian cancer	0.000207	0.000923	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—ovarian cancer	0.000207	0.000921	CcSEcCtD
Dihydroergotamine—Nausea—Paclitaxel—ovarian cancer	0.000206	0.000921	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—ovarian cancer	0.000205	0.000913	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—ovarian cancer	0.000203	0.000906	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—ovarian cancer	0.000203	0.000904	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—ovarian cancer	0.000202	0.000903	CcSEcCtD
Dihydroergotamine—ADRA2A—gonad—ovarian cancer	0.000202	0.0282	CbGeAlD
Dihydroergotamine—Diarrhoea—Docetaxel—ovarian cancer	0.000202	0.000899	CcSEcCtD
Dihydroergotamine—ADRA2A—uterus—ovarian cancer	0.000201	0.0281	CbGeAlD
Dihydroergotamine—Confusional state—Epirubicin—ovarian cancer	0.0002	0.000893	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—ovarian cancer	0.000199	0.000888	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—ovarian cancer	0.000199	0.000886	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—ovarian cancer	0.000196	0.000872	CcSEcCtD
Dihydroergotamine—Dizziness—Docetaxel—ovarian cancer	0.000195	0.000869	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—ovarian cancer	0.000195	0.000867	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—ovarian cancer	0.000194	0.000865	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000192	0.000857	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—ovarian cancer	0.000192	0.000855	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—ovarian cancer	0.000192	0.000855	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—ovarian cancer	0.000191	0.000852	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—ovarian cancer	0.00019	0.000845	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—ovarian cancer	0.000189	0.000845	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—ovarian cancer	0.000188	0.000836	CcSEcCtD
Dihydroergotamine—Vomiting—Docetaxel—ovarian cancer	0.000187	0.000835	CcSEcCtD
Dihydroergotamine—Rash—Docetaxel—ovarian cancer	0.000186	0.000828	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—ovarian cancer	0.000186	0.000828	CcSEcCtD
Dihydroergotamine—Dermatitis—Docetaxel—ovarian cancer	0.000186	0.000828	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—ovarian cancer	0.000185	0.000827	CcSEcCtD
Dihydroergotamine—Headache—Docetaxel—ovarian cancer	0.000185	0.000823	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—ovarian cancer	0.000184	0.00082	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000181	0.000807	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—ovarian cancer	0.000181	0.000807	CcSEcCtD
Dihydroergotamine—ADRA2A—female reproductive system—ovarian cancer	0.000181	0.0252	CbGeAlD
Dihydroergotamine—Insomnia—Epirubicin—ovarian cancer	0.00018	0.000801	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—ovarian cancer	0.000179	0.0008	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—ovarian cancer	0.000178	0.000796	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000178	0.000793	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—ovarian cancer	0.000177	0.00079	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—ovarian cancer	0.000177	0.000788	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—ovarian cancer	0.000175	0.000782	CcSEcCtD
Dihydroergotamine—Nausea—Docetaxel—ovarian cancer	0.000175	0.00078	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—ovarian cancer	0.000175	0.00078	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—ovarian cancer	0.000173	0.00077	CcSEcCtD
Dihydroergotamine—ABCB1—myometrium—ovarian cancer	0.000173	0.0241	CbGeAlD
Dihydroergotamine—Hypotension—Doxorubicin—ovarian cancer	0.000172	0.000766	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—ovarian cancer	0.000171	0.000764	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—ovarian cancer	0.00017	0.000758	CcSEcCtD
Dihydroergotamine—HTR2B—lymph node—ovarian cancer	0.000168	0.0235	CbGeAlD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000168	0.000747	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—ovarian cancer	0.000166	0.000742	CcSEcCtD
Dihydroergotamine—ABCB1—embryo—ovarian cancer	0.000166	0.0232	CbGeAlD
Dihydroergotamine—Paraesthesia—Doxorubicin—ovarian cancer	0.000165	0.000736	CcSEcCtD
Dihydroergotamine—ADRA2A—female gonad—ovarian cancer	0.000164	0.023	CbGeAlD
Dihydroergotamine—Dyspnoea—Doxorubicin—ovarian cancer	0.000164	0.000731	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—ovarian cancer	0.000164	0.00073	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—ovarian cancer	0.000163	0.000729	CcSEcCtD
Dihydroergotamine—ADRA2A—vagina—ovarian cancer	0.000163	0.0228	CbGeAlD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000162	0.000725	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—ovarian cancer	0.000162	0.000722	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—ovarian cancer	0.00016	0.000713	CcSEcCtD
Dihydroergotamine—Ergotamine—ABCB1—ovarian cancer	0.000159	0.509	CrCbGaD
Dihydroergotamine—Fatigue—Doxorubicin—ovarian cancer	0.000159	0.000707	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—ovarian cancer	0.000158	0.000704	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—ovarian cancer	0.000157	0.000701	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—ovarian cancer	0.000157	0.0007	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—ovarian cancer	0.000157	0.0007	CcSEcCtD
Dihydroergotamine—Bromocriptine—ABCB1—ovarian cancer	0.000153	0.491	CrCbGaD
Dihydroergotamine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000152	0.000676	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00015	0.00067	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—ovarian cancer	0.000146	0.000653	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—ovarian cancer	0.000146	0.000651	CcSEcCtD
Dihydroergotamine—ADRA2A—testis—ovarian cancer	0.000146	0.0204	CbGeAlD
Dihydroergotamine—Abdominal pain—Doxorubicin—ovarian cancer	0.000145	0.000648	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—ovarian cancer	0.000145	0.000648	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—ovarian cancer	0.000143	0.000636	CcSEcCtD
Dihydroergotamine—CYP3A4—female reproductive system—ovarian cancer	0.000142	0.0199	CbGeAlD
Dihydroergotamine—Pruritus—Epirubicin—ovarian cancer	0.000141	0.000627	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—ovarian cancer	0.000136	0.000606	CcSEcCtD
Dihydroergotamine—ABCB1—epithelium—ovarian cancer	0.000135	0.0189	CbGeAlD
Dihydroergotamine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000135	0.000604	CcSEcCtD
Dihydroergotamine—ABCB1—uterine cervix—ovarian cancer	0.000134	0.0188	CbGeAlD
Dihydroergotamine—Asthenia—Doxorubicin—ovarian cancer	0.000132	0.000588	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—ovarian cancer	0.000131	0.000586	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—ovarian cancer	0.00013	0.00058	CcSEcCtD
Dihydroergotamine—ABCB1—decidua—ovarian cancer	0.000128	0.0179	CbGeAlD
Dihydroergotamine—Vomiting—Epirubicin—ovarian cancer	0.000126	0.000563	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—ovarian cancer	0.000126	0.000561	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—ovarian cancer	0.000125	0.000559	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—ovarian cancer	0.000125	0.000558	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—ovarian cancer	0.000124	0.000555	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—ovarian cancer	0.000122	0.000542	CcSEcCtD
Dihydroergotamine—ABCB1—endometrium—ovarian cancer	0.000121	0.017	CbGeAlD
Dihydroergotamine—Nausea—Epirubicin—ovarian cancer	0.000118	0.000526	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—ovarian cancer	0.000117	0.000521	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—ovarian cancer	0.000116	0.000517	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—ovarian cancer	0.000116	0.000516	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—ovarian cancer	0.000115	0.000514	CcSEcCtD
Dihydroergotamine—ABCB1—gonad—ovarian cancer	0.000113	0.0157	CbGeAlD
Dihydroergotamine—ABCB1—uterus—ovarian cancer	0.000112	0.0156	CbGeAlD
Dihydroergotamine—Nausea—Doxorubicin—ovarian cancer	0.000109	0.000487	CcSEcCtD
Dihydroergotamine—ADRA2A—lymph node—ovarian cancer	0.000106	0.0148	CbGeAlD
Dihydroergotamine—ABCB1—female reproductive system—ovarian cancer	0.000101	0.0141	CbGeAlD
Dihydroergotamine—ABCB1—bone marrow—ovarian cancer	9.5e-05	0.0133	CbGeAlD
Dihydroergotamine—ABCB1—female gonad—ovarian cancer	9.16e-05	0.0128	CbGeAlD
Dihydroergotamine—ABCB1—vagina—ovarian cancer	9.1e-05	0.0127	CbGeAlD
Dihydroergotamine—ABCB1—testis—ovarian cancer	8.12e-05	0.0113	CbGeAlD
Dihydroergotamine—ABCB1—lymph node—ovarian cancer	5.89e-05	0.00822	CbGeAlD
